InsightRX to Present Vancomycin PK Model, MIPD Protocols at ACoP15

SAN FRANCISCO, Oct. 29, 2024 – InsightRX, a leader in Bayesian model-informed precision dosing (MIPD) software, has announced that it will present two significant research abstracts at the upcoming American Conference on Pharmacometrics (ACoP15), scheduled for Nov. 10-13 at the Arizona Grand Resort in Phoenix.

The American Conference on Pharmacometrics (ACoP) is the yearly scientific event organized by the International Society of Pharmacometrics (ISoP) and is dedicated to all aspects of modeling and simulation in pharmacology and therapeutics. This year marks the 15th annual ACoP event.

The presentations from InsightRX include the following research abstracts:

Poster Presentation: "Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context"
Date: Monday, Nov. 11
Time: 7 a.m. to 5 p.m. MST
Presenter: Dominic Tong, Ph.D., Senior Data Scientist at InsightRX
Collaborators: Jasmine Hughes, Ph.D., Director of Data Science at InsightRX, and Ron Keizer, PharmD, Ph.D., Chief Scientific Officer at InsightRX
Summary: This study examines Cystatin C (CYSC) and serum creatinine (CR), two biomarkers used to estimate glomerular filtration rate (GFR), a critical marker of kidney function. Accurate estimation of kidney function is essential for determining drug clearance in population pharmacokinetic (popPK) models. InsightRX researchers compared the performance of CR-based and CYSC-based popPK models for adult patients receiving vancomycin. The study also evaluates whether a refit model using one or both biomarkers improves the prediction of vancomycin levels.

Poster Presentation: "mipdtrial: an open-source R package for simulating model-informed precision dosing trials"
Date: Monday, Nov. 11
Time: 7 a.m. to 5 p.m. MST
Presenter: Jasmine Hughes, Director of Data Science at InsightRX
Collaborators: Jordan Brooks, Ph.D., PharmD, Pharmacometrician at InsightRX; Ron Keizer, Ph.D., PharmD, Chief Scientist at InsightRX; Dominic Tong, Ph.D., Senior Data Scientist at InsightRX
Summary: The effectiveness of model-informed precision dosing (MIPD) protocols depends on various factors, including biomarker sample timing, dose selection algorithms, and model appropriateness. The numerous parameters that can be optimized in MIPD protocols make prospective clinical trials challenging for data-driven protocol development. Simulation allows for the examination of these protocol parameters to ensure successful implementation of MIPD in clinical trials or routine practice. This poster details how InsightRX researchers developed an R package that provides tools for simulating MIPD treatment courses, assessing the relationship between protocol parameters and achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.

"We are excited to present our research at ACoP15 and to discuss the advancements in model-informed precision dosing, particularly in improving the accuracy of antibiotic dosing," said Sirj Goswami, PhD, CEO and cofounder of InsightRX. "By sharing our insights with the pharmacometric community, we can demonstrate how MIPD can enhance clinical outcomes and operational efficiency."

InsightRX is a healthcare technology company that offers a cloud-based clinical decision support platform incorporating quantitative pharmacology and artificial intelligence (AI) to enhance therapeutic decision-making from phase I drug development to patient care. The platform provides an individualized, predictive understanding of a patient's response to treatment, helping clinicians improve medication effectiveness by better understanding dose-effect response and toxicity.